You are here:

guanfacine hydrochloride (Intuniv)

Advice

following a full submission:

guanfacine (Intuniv®) is accepted for use within NHS Scotland.

Indication under review: treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures. 

Two phase III studies in children and adolescents aged 6 to 17 years with ADHD demonstrated that guanfacine improved the symptoms of ADHD compared with placebo.

 

Drug Details

Drug Name: guanfacine hydrochloride (Intuniv)
SMC Drug ID: 1123/16
Manufacturer: Shire Pharmaceuticals
Indication: treatment of attention deficit hyperactivity disorder (ADHD) in children and adolescents 6 to 17 years old for whom stimulants are not suitable, not tolerated or have been shown to be ineffective. Treatment must be used as part of a comprehensive ADHD treatment programme, typically including psychological, educational and social measures.
BNF Category:
Sub Category: 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
Submission Type: Full submission
Status: Accepted
Date Advice Published: 7 February 2016

Back